GPR120とPPARγのフラボノイドベースの二重調節:代謝疾患への介入における潜在的な治療戦略

Geetanjali B Gone¹, Yenogmok Kim¹, Ye-Seul Song²

¹Department of Biopharmaceutical Convergence, School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.

Bioorganic chemistry

|August 22, 2025

まとめ

研究者たちは新しい化合物を特定しました

科学分野:

薬剤化学
内分泌学
代謝障害

背景:

2型糖尿病 (T2DM) は新しい治療戦略を必要とします.
Gタンパク質結合受容体120 (GPR120) は重要な代謝調節体ですが,強力なアゴニストは限られています.
新しいGPR120アゴニストの開発はT2DM治療に不可欠です.

研究の目的:

新しいフラボンとイソフラボン誘導体を設計し合成する.
潜在的T2DM治療薬のための強力なGPR120アゴニストを特定する.
鉛化合物の代謝効果と二重作用の可能性を評価する.

主な方法:

16種類のフラボンとイソフラボン誘導体の合成
GPR120アゴニズム,グルコース吸収,アディポゲネシスを評価するために3T3-L1アディポサイトを用いたインビトロ検査.
系統的代謝効果を評価するためにゼブラフィッシュの幼虫モデルを用いた in vivo 研究.
ペロキシソーム増殖剤活性化ガマ受容体 (PPARγ) 抗剤の活性に関する評価

主要な成果:

4',5,7-トリメトキシフラボン (15) は,最も強力なGPR120アゴニスト (EC50 = 0. 6μM) として現れました.
化合物15は,GPR120媒介のAMPKリン酸化によってグルコースの吸収を増加させ,アディポゲネシスを減少させた.
ゼブラフィッシュにおける15の調節された前インスリンマーカーであり,有意なPPARγアンタゴニスト活性を示した.

結論:

4',5,7-トリメトキシフラボン (15) は,二重の代謝調節機能を持つ強力なGPR120アゴニストである.
化合物15はT2DMと代謝症候群に対するより安全で二重作用の治療法の開発の先導体として有望である.
複合体15のGPR120アゴニズムとPPARγアゴニズムは,新しい治療方法を提供する.

キーワード:

AMPK についてアンチアディポゲン抗糖尿病剤フラボノイド GPR120 について PPARγ について

さらに関連する動画

11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.2K

07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

545

関連する概念動画

01:15

G Protein-coupled Receptors

13.3K

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

13.3K

01:24

Glucagon-like Receptor Agonists

416

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

416

01:31

Transducer Mechanism: Nuclear Receptors

1.6K

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

1.6K

01:19

Regulation of Metabolism

9.9K

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...

9.9K

01:09

GPCRs Regulate Adenylyl Cylase Activity

5.9K

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...

5.9K

01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.8K

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: